Satoshi Ishitoya

Satoshi Ishitoya

Auto-generated profile, based on publicly available information

Satoshi Ishitoya

Department of Urology, Japanese Red Cross Otsu Hospital, Shiga, Japan

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2021 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
KMKei Mizuno
Kei Mizuno
TSTakayuki Sumiyoshi
Takayuki Sumiyoshi
TOTakatsugu Okegawa
Takatsugu Okegawa
NTNaoki Terada
Naoki Terada
SISatoshi Ishitoya
Satoshi Ishitoya
SAShusuke Akamatsu
Shusuke Akamatsu
Purpose: Although cell-free DNA (cfDNA) testing is expected to drive cancer precision medicine, little is known about the significance of detecting low-frequency variants in circulating cell-free tumor DNA (ctDNA) in castration-resistant prostate cancer (CRPC). We aimed to identify genomic profile including low-frequency variants in ctDNA from patients with CRPC and investigate the clinical utility of detecting variants with variant allele frequency (VAF) below 1%. Experimental Design: This prospective, multicenter cohort study enrolled patients with CRPC eligible for treatment with abiraterone or enzalutamide. We performed targeted sequencing of pretreatment cfDNA and paired leukocyte DNA with molecular barcodes, and ctDNA variants with a VAF ≥0.1% were detected using an in-house pipeline. We investigated progression-free survival (PFS) and overall survival (OS) after different ctDNA fraction cutoffs were applied. Results: One hundred patients were analyzed (median follow-up 10.7 months). We detected deleterious ATM, BRCA2, and TP53 variants even in samples with ctDNA fraction below 2%. When the ctDNA fraction cutoff value of 0.4% was applied, significant differences in PFS and OS were found between patients with and without defects in ATM or BRCA2 [HR, 2.52; 95% confidence interval (CI), 1.24–5.11; P = 0.0091] and TP53 (HR, 3.74; 95% CI, 1.60–8.71; P = 0.0014). However, these differences were no longer observed when the ctDNA fraction cutoff value of 2% was applied, and approximately 50% of the samples were classified as ctDNA unquantifiable. Conclusions: Detecting low-frequency ctDNA variants with a VAF <1% is important to identify clinically informative genomic alterations in CRPC.

1 December 2000 in Journal of Urology
Verified
Journal Article
Closed access
ATAkito Terai
Akito Terai
SISatoshi Ishitoya
Satoshi Ishitoya
KMKenji Mitsumori
Kenji Mitsumori
OOOsamu Ogawa
Osamu Ogawa
Conclusions Our results are consistent with the ascending route of infection in acute bacterial prostatitis. However, causative E. coli might possibly originate from either intestinal reservoir of the host or household member. Owing to limitations of the cross-sectional design of this study, longitudinal studies are necessary to establish the ascending route of infection in this disease.

28 July 2025 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
SKShigeki Koterazawa
Shigeki Koterazawa
TGTakayuki Goto
Takayuki Goto
MKMasashi Kubota
Masashi Kubota
KMKei Mizuno
Kei Mizuno
TSTakayuki Sumiyoshi
Takayuki Sumiyoshi
TKTakashi Kobayashi
Takashi Kobayashi

31 March 2023
Verified
Other
Open access
KMKei Mizuno
Kei Mizuno
TSTakayuki Sumiyoshi
Takayuki Sumiyoshi
TOTakatsugu Okegawa
Takatsugu Okegawa
NTNaoki Terada
Naoki Terada
SISatoshi Ishitoya
Satoshi Ishitoya
SAShusuke Akamatsu
Shusuke Akamatsu
Purpose:Although cell-free DNA (cfDNA) testing is expected to drive cancer precision medicine, little is known about the significance of detecting low-frequency variants in circulating cell-free tumor DNA (ctDNA) in castration-resistant prostate cancer (CRPC). We aimed to identify genomic profile including low-frequency variants in ctDNA from patients with CRPC and investigate the clinical utility of detecting variants with variant allele frequency (VAF) below 1%.Experimental Design:This prospective, multicenter cohort study enrolled patients with CRPC eligible for treatment with abiraterone or enzalutamide. We performed targeted sequencing of pretreatment cfDNA and paired leukocyte DNA with molecular barcodes, and ctDNA variants with a VAF ≥0.1% were detected using an in-house pipeline. We investigated progression-free survival (PFS) and overall survival (OS) after different ctDNA fraction cutoffs were applied.Results:One hundred patients were analyzed (median follow-up 10.7 months). We detected deleterious ATM, BRCA2, and TP53 variants even in samples with ctDNA fraction below 2%. When the ctDNA fraction cutoff value of 0.4% was applied, significant differences in PFS and OS were found between patients with and without defects in ATM or BRCA2 [HR, 2.52; 95% confidence interval (CI), 1.24–5.11; P = 0.0091] and TP53 (HR, 3.74; 95% CI, 1.60–8.71; P = 0.0014). However, these differences were no longer observed when the ctDNA fraction cutoff value of 2% was applied, and approximately 50% of the samples were classified as ctDNA unquantifiable.Conclusions:Detecting low-frequency ctDNA variants with a VAF <1% is important to identify clinically informative genomic alterations in CRPC.

31 March 2023
Verified
Other
Open access
KMKei Mizuno
Kei Mizuno
TSTakayuki Sumiyoshi
Takayuki Sumiyoshi
TOTakatsugu Okegawa
Takatsugu Okegawa
NTNaoki Terada
Naoki Terada
SISatoshi Ishitoya
Satoshi Ishitoya
SAShusuke Akamatsu
Shusuke Akamatsu
Supplementary Data includes Supplementary Methods, Supplementary Results, Supplementary Table S1-S13, Supplementary Figure S1-S7, and Supplementary References.

31 March 2023
Verified
Other
Open access
KMKei Mizuno
Kei Mizuno
TSTakayuki Sumiyoshi
Takayuki Sumiyoshi
TOTakatsugu Okegawa
Takatsugu Okegawa
NTNaoki Terada
Naoki Terada
SISatoshi Ishitoya
Satoshi Ishitoya
SAShusuke Akamatsu
Shusuke Akamatsu
Purpose:Although cell-free DNA (cfDNA) testing is expected to drive cancer precision medicine, little is known about the significance of detecting low-frequency variants in circulating cell-free tumor DNA (ctDNA) in castration-resistant prostate cancer (CRPC). We aimed to identify genomic profile including low-frequency variants in ctDNA from patients with CRPC and investigate the clinical utility of detecting variants with variant allele frequency (VAF) below 1%.Experimental Design:This prospective, multicenter cohort study enrolled patients with CRPC eligible for treatment with abiraterone or enzalutamide. We performed targeted sequencing of pretreatment cfDNA and paired leukocyte DNA with molecular barcodes, and ctDNA variants with a VAF ≥0.1% were detected using an in-house pipeline. We investigated progression-free survival (PFS) and overall survival (OS) after different ctDNA fraction cutoffs were applied.Results:One hundred patients were analyzed (median follow-up 10.7 months). We detected deleterious ATM, BRCA2, and TP53 variants even in samples with ctDNA fraction below 2%. When the ctDNA fraction cutoff value of 0.4% was applied, significant differences in PFS and OS were found between patients with and without defects in ATM or BRCA2 [HR, 2.52; 95% confidence interval (CI), 1.24–5.11; P = 0.0091] and TP53 (HR, 3.74; 95% CI, 1.60–8.71; P = 0.0014). However, these differences were no longer observed when the ctDNA fraction cutoff value of 2% was applied, and approximately 50% of the samples were classified as ctDNA unquantifiable.Conclusions:Detecting low-frequency ctDNA variants with a VAF <1% is important to identify clinically informative genomic alterations in CRPC.